20-Mar-2017 - Eurofins Scientific Services NV

Eurofins to invest millions in new UK facility

Eurofins Scientific (EUFI.PA), a world leader in bioanalytical testing, has announced plans to establish a new pharmaceutical chemistry and microbiology facility in Livingston, Scotland as part of a £4 million investment.

The announcement follows Eurofins’ acquisition of Exova’s pharmaceutical, food and water testing business in the UK & Ireland in July 2016, and the subsequent purchase of ILS’s pharmaceutical business in October 2016.

Significantly increasing its capacity in the UK, the 5800 m2 facility at Brucefield Industry Park will house Eurofins’ Biopharmaceutical Testing business in the UK, currently based in Edinburgh. The first phase of the project will see the development of 1400m2 of lab space and creates the scope for significant expansion.

Alison Clayton, general manager at Eurofins BioPharma Product Testing commented: “It’s an exciting time for Eurofins as we strengthen our footprint in the UK and Ireland. The new facility offers significant capacity for future growth, as well as the space to take on new projects more rapidly and react to customer needs more flexibly.

“The purpose-built lab space will also help to improve productivity, meaning we can provide a more streamlined and efficient service to biopharmaceutical companies accessing our analytical testing services.

“From the new facility, Eurofins BioPharma Product Testing UK will provide a range of GMP pharmaceutical testing services, including, but not exclusively method development and validation, finished product and raw material testing, elemental impurity testing, micro testing and stability studies.”

As part of the investment, Eurofins BioPharma Product Testing UK will be purchasing a new inductively coupled plasma mass spectrometry (ICP-MS) machine, enabling the company to meet growing demand for this service. Eurofins will also invest in more high-performance liquid chromatography (HPLC) equipment, increasing its capacity by 40 per cent.

Alison continued: “At Eurofins BioPharma Product Testing UK, we are committed to adapting and growing our offering in line with customers’ evolving needs. Following the introduction of the International Conference on Harmonization (ICH), Q3D Guideline for Elemental Impurities relating to existing drug products in the US and Europe, we have seen greater demand for more quantitative methods of elemental analysis such as the use of ICP-MS technology.

“From the 1st January 2018, these regulations will apply to both new and existing drug products, so by investing now, we are preparing for future demand and market requirements.”

Eurofins Scientific Services NV

Recommend news PDF version / Print

Share on

Facts, background information, dossiers
  • Eurofins
  • testing services
  • pharmaceutical chemistry
  • microbiology
  • method development
  • investments
More about Eurofins
  • News

    Eurofins scientific acquires two North American companies

    By acquiring EnvironeX Group Inc. in Canada and TestAmerica in the USA Eurofins expands its testing capabilities in the North American market. EnvironeX Group Inc. - bioanalytical testing in Canada Founded in 2005 by Marc Hamilton and supported by PCP since 2015, EnvironeX is a leading prov ... more

    Eurofins closes acquisition of cosmetic testing lab in France

    Eurofins Scientific announces that it has successfully closed the acquisition of Laboratoire Dermscan SAS (“Dermscan”), a leading provider of Cosmetic & Personal Care Products Testing services in Europe. Dermscan was founded in 1990 in Lyon as a family-owned business. After nearly three dec ... more

    Eurofins acquires German pharma quality service company

    Eurofins Scientific announces that it has signed an exclusive agreement to acquire PHAST Gesellschaft für Pharmazeutische Qualitätsstandards mbH (“PHAST”), one of Europe’s leading service providers in the field of pharmaceutical products quality. The transaction is expected to close in the ... more